SCHEMBL655742

SCHEMBL655742

On1[c]nc2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
MAPK1 P28482 1/20 0.48
ATM Q13315 1/20 0.48
DGAT1 O75907 1/20 0.35
MAPT P10636 2/20 0.34
ALDH1A1 P00352 2/20 0.34
SLC9A1 P19634 1/20 0.34
KEAP1 Q14145 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
THPO P40225 1/20 0.34
CYP4Z1 Q86W10 1/20 0.34
KDM4E B2RXH2 4/20 0.34
LMNA P02545 3/20 0.34
MEN1 O00255 2/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16097481 0.74 SLC9A1 (0.36) POLBMAPK1ATMMAPTALDH1A1
SCHEMBL2073661 0.73 POLB (0.39) POLBMAPK1ATMMAPTALDH1A1
SCHEMBL1264258 0.73 MAPT (0.43) POLBMAPK1ATMMAPTALDH1A1
SCHEMBL811367 0.73 ATM (0.39) POLBMAPK1ATMDGAT1MAPT
SCHEMBL75687 0.73 SLC9A1 (0.43) POLBMAPK1ATMMAPTALDH1A1
SCHEMBL407498 0.73 POLB (0.39) POLBMAPK1ATMDGAT1MAPT
SCHEMBL558259 0.73 ATM (0.39) POLBMAPK1ATMDGAT1MAPT
SCHEMBL1491295 0.72 ENPP2 (0.41) ALDH1A1CYP3A4KDM4EMEN1KMT2A
SCHEMBL1491376 0.72 ENPP2 (0.41) ALDH1A1KEAP1KDM4EMEN1KMT2A
SCHEMBL2103982 0.72 POLB (0.39) POLBMAPK1ATMDGAT1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110713588-B Hardmask composition, hardmask layer and method of forming pattern 三星SDI株式会社 2022-08-09 CN claimed
US-11214678-B2 Hardmask composition, hardmask layer and method of forming patterns SAMSUNG SDI CO., LTD. (KR) 2022-01-04 US claimed
CN-110713588-A Hardmask composition, hardmask layer and method of forming pattern 三星SDI株式会社 2020-01-21 CN claimed
US-10472360-B2 Purine diones as Wnt pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-11-12 US claimed
US-20170334912-A1 Purine Diones As Wnt Pathway Modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-11-23 US claimed
EP-2428577-B1 Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters EASTMAN CHEM CO (US) 2014-01-22 EP claimed
WO-2010043711-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2010-04-22 WO claimed
EP-2177510-A1 Allosteric protein kinase modulators Universität des Saarlandes (DE) 2010-04-21 EP claimed
CN-110713588-B Hardmask composition, hardmask layer and method of forming pattern 三星SDI株式会社 2022-08-09 CN disclosed
US-11214678-B2 Hardmask composition, hardmask layer and method of forming patterns SAMSUNG SDI CO., LTD. (KR) 2022-01-04 US disclosed
CN-110713588-A Hardmask composition, hardmask layer and method of forming pattern 三星SDI株式会社 2020-01-21 CN disclosed
CN-104529906-A Method for improving water solubility of hydroxybenzimidazolyl compound TIANJIN INST PHARM RESEARCH 2015-04-22 CN disclosed
CN-104529906-A Method for improving water solubility of hydroxybenzimidazolyl compound TIANJIN INST PHARM RESEARCH 2015-04-22 CN disclosed
US-8912186-B2 Allosteric protein kinase modulators UNIVERSITAET DES SAARLANDES (DE) 2014-12-16 US disclosed
US-7935706-B2 Nitrogen-containing heterocycle derivatives substituted with cyclic group SHIONOGI & CO., LTD. (JP) 2011-05-03 US disclosed
WO-2011029832-A1 NOVEL THIAZOL AND OXAZOL HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2011-03-17 WO disclosed
WO-2010043711-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2010-04-22 WO disclosed
EP-2177510-A1 Allosteric protein kinase modulators Universität des Saarlandes (DE) 2010-04-21 EP disclosed
US-20090062261-A1 NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP SHIONOGI & CO., LTD. (JP) 2009-03-05 US disclosed
EP-1988077-A1 NIROGENOUS HETEROCYCLIC DERIVATIVES SUBSTITUTED WITH CYCLIC GROUPS SHIONOGI & CO., LTD. (JP) 2008-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334912-A1 Purine Diones As Wnt Pathway Modulators WNT1, WNT3A, CTNNB1 POLB 1739/4885MAPK1 920/4885ATM 1515/4885
US-10472360-B2 Purine diones as Wnt pathway modulators WNT1, WNT3A, CTNNB1 POLB 1739/4885MAPK1 920/4885ATM 1515/4885
US-20090062261-A1 NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP NR4A1, NR0B2, NR0B1 POLB 3861/4885MAPK1 1586/4885ATM 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.